Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines

Journal of Virology

Volumn 72, Issue 2, 1998, Pages 1552-1576

  Connor, R I ^a   Korber, B T M ^b   Graham, B S ^c   Hahn, B H ^d   Ho, D D ^a   Walker, B D ^e   Neumann, A U ^b   Vermund, S H ^d   Mestecky, J ^d   Jackson, S ^d   Fenamore, E ^a   Cao, Y ^a   Gao, F ^d   Kalams, S ^e   Kunstman, K J ^f   Mcdonald, D ^b   Mcwilliams, N ^f   Trkola, A ^a   Moore, J P ^a   Wolinsky, S M ^f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120 SUBUNIT VACCINE; RPG 120; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENVELOPE GENE; GENETIC ANALYSIS; GENETIC SELECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYLOGENY; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 0031906149     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.2.1552-1576.1998     Document Type: Article

References (158)

1. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, J. S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11:533-540.
2. Altschul, S. F., W. Gish, W. Miller, and E. W. Myers. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
3. Artenstein, A. W., T. C. VanCott, K. V. Sitz, M. L. Robb, K. F. Wagner, S. C. D. Veit, A. F. Rogers, R. P. Garner, J. W. Byron, P. R. Burnett, and D. L. Birx. 1997. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J. Infect. Dis. 175:265-271.
4. Åsjö, B., L. Morfeldt-Månson, J. Albert, G. Biberfeld, A. Karlsson, K. Lidman, and E. M. Fenyö. 1986. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet i:660-662.
5. Baenziger, J., Y. Liu, and C. Walker. 1994. Cytotoxic T lymphocyte (CTL) responses in baboons and humans immunized with a recombinant HIV-1 gp120 vaccine, p. 88. In Proceedings of the Seventh Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, Va.
6. Belshe, R. B., B. S. Graham, M. C. Keefer, G. J. Gorse, P. Wright, R. Dolin, T. Matthews, K. Weinhold, D. P. Bolognesi, R. Sposto, D. M. Stablein, T. Twaddell, P. W. Berman, T. Gregory, A. E. Izu, M. C. Walker, and P. Fast for the NIAID AIDS Vaccine Clinical Trials Network. 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272:475-480.
7. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622-625.
8. Berman, P. W., J. E. Groopman, T. Gregory, P. R. Clapham, R. A. Weiss, R. Ferriani, L. Riddle, C. Shimasaki, C. Lucas, L. A. Lasky, and J. W. Eichberg. 1988. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 85:5200-5204.
9. Berman, P. W., T. J. Matthews, L. Riddle, M. Champe, M. R. Hobbs, G. R. Nakamura, J. Mercer, D. J. Eastman, C. Lucas, A. J. Langlois, F. M. Wurm, and T. J. Gregory. 1992. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:4464-4469.
10. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obijeski. 1996. Protection of MN rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:52-59.
11. Berman, P. W., L. Riddle, G. Nakamura, O. K. Haffar, W. M. Nunes, P. Skehel, R. Byrn, J. Groopman, T. Matthews, and T. Gregory. 1989. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J. Virol. 63:3489-3498.
12. Binley, J. M., P. J. Klasse, Y. Cao, I. Jones, M. Markowitz, D. D. Ho, and J. P. Moore. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71:2799-2809.
13. Blouin, J. C., E. A. Guzman, and B. Foley. 1996. Global variation in the HIV-1 V3 region, p. 29-41. In G. Myers, B. Korber, B. Foley, K.-T. Jeang, J. W. Mellors, and S. Wain-Hobson (ed.), Human retroviruses and AIDS compendium, vol. III. Los Alamos National Laboratory, Los Alamos, N.Mex.
14. Bolognesi, D. P., L. Corey, S. H. Vermund, and D. F. Both. 1994. HIV vaccine development: a progress report. Ann. Intern. Med. 8:603-611.
15. Bruck, C., C. Thiriart, L. Fabry, M. Francotte, P. Pala, O. Van Opstal, J. Culp, M. Rosenberg, M. De Wilde, P. Heidt, and J. Heeney. 1994. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12:1141-1148.
16. Burton, D. R., J. Pyati, R. Koduri, G. B. Thornton, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
17. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
18. Capon, D. J., S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory, H. Mitsuya, R. A. Byrn, C. Lucas, F. M. Wurm, J. E. Groopman, and D. H. Smith. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531.
19. Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
20. Casteel, L. R., S. Allen, R. Kulhavy, I. Zulu, J. Omara, and J. Mestecky. 1997. HIV-specific antibodies in external secretions of seronegative and seropositive high-risk individuals, abstr. 73, p. 178. In Proceedings of the 9th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS.
21. Chakrabarti, L., M.-C. Cumont, L. Montagnier, and B. Hurtrel. 1994. Variable course of primary simian immunodeficiency virus infection in lymph nodes: relationship to disease progression. J. Virol. 68:6634-6642.
22. Chesney, M. A., P. Lurie, and T. J. Coates. 1995. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J. Acquired Immune Defic. Syndr. 9:30-35.
23. Conley, A. J., J. A. Kessler II, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348-3352.
24. Conley, A. J., J. A. Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
25. Connor, R. I., and D. D. Ho. 1994. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 68:4400-4408.
26. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185:621-628.
27. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87:6574-6578.
28. Daniel, M. D., G. P. Mazzara, M. A. Simon, P. K. Sehgal, T. Kodama, D. L. Panicali, and R. C. Desrosiers. 1994. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retroviruses 10:839-851.
29. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, and ALIVE Study. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural allele. Science 273:1856-1862.
30. Deng, H. K., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
31. de St. Groth, F. 1982. The evaluation of limiting dilution assays. J. Immunol. Methods 49:R11-R23.
32. Doe, B., Y. Liu, K. S. Steimer, and C. M. Walker. 1994. Priming of cytotoxic T lymphocyte responses with recombinant HIV envelope proteins in murine and primate models, p. 321-325. In M. Girard and L. Valette (ed.), Retroviruses of human AIDS and related animal diseases, 7th Colloque des Cent Gardes. La Fondiation Marcel Mèrieau, Marnes-La-Coquette, France.
33. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
34. D'Souza, M. P., and V. A. Harden. 1996. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat. Med. 2:1293-1300.
35. D'Souza, M. P., D. Livnat, J. A. Bradac, S. H. Bridges, the AIDS Clinical Trials Group Antibody Selection Working Group, and collaborating investigators. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis., in press.
36. Eddy, S., G. Mitchison, and R. Durbin. 1995. Maximum discrimination hidden Markov models of sequence consensus. J. Comp. Biol. 2:9-23.
37. El-Amed, Z., K. K. Murthy, K. Higgins, E. K. Cobb, N. L. Haigwood, J. A. Levy, and K. S. Steimer. 1995. Resistance of chimpanzees immunized with recombinant gp120 SF-2 to challenge by HIV-1 SF-2. AIDS 9:1313-1322.
38. Emini, E. A., W. A. Schlief, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. M. Eichberg, and K. K. Murthy. 1991. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
39. Faulkner, D. V., and A. Jurka. 1988. Multiple aligned sequence editor (MASE). Trends Biochem. Sci. 13:321-326.
40. Felsenstein, J. 1981. Evolutionary trees from DNA sequences: a maximum likelihood approach. J. Mol. Evol. 17:368-376.
41. Felsenstein, J. 1985. Confidence on phytogenies: an approach using the bootstrap. Evolution 39:783-791.
42. Felsenstein, J. 1988. Phytogenies from molecular sequences: inference and reliability. Annu. Rev. Genet. 22:521-565.
43. Felsenstein, J. 1989. PHYLIP - phylogenetic inference package (version 3.2). Cladistics 5:164-166.
44. Felsenstein, J. 1993. PHYLIP (phylogenetic inference package) version 3.4. Department of Genetics, University of Washington, Seattle. (Distributed by the author.)
45. Ferbas, J., E. S. Daar, K. Grovit-Ferbas, W. J. Lech, R. Detels, J. V. Giorgi, and A. H. Kaplan. 1996. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J. Virol. 70:7285-7289.
46. Fiore, J. R., A. Björndal, K. A. Peipke, M. di Stefano, G. Angarano, G. Pasture, H. Gaines, E. M. Fenyö, and J. Albert. 1994. The biological phenotype of HIV-1 is usually retained after sexual transmission. Virology 204:297-303.
47. Fouchier, R. A. M., M. Groenink, N. A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
48. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71: 2779-2785.
49. Fultz, P. N., P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard. 1992. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 256:1687-1690.
50. Fung, M. S. C., C. R. Y. Sun, W. L. Gordon, R.-S. Liou, T. W. Chang, W. N. C. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
51. Gao, F., S. G. Morrison, D. L. Robertson, C. L. Thornton, S. Craig, G. Karlsson, J. Sodroski, M. Morgado, B. Galvao-Castro, H. von Briesen, S. Beddows, J. Weber, P. M. Sharp, G. M. Shaw, B. H. Hahn, and the WHO and NIAID Networks for HIV Isolation and Characterization. 1996. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 70:1651-1667.
52. 6/1. AIDS 11:53-57.
53. Girard, M., M.-P. Kieny, A. Pinter, F. Barré-Sinoussi, P. Nara, H. Kolbe, K. Kusumi, A. Chaput, T. Reinhart, E. Muchmore, J. Roneo, M. Kaczorek, E. Gomard, J.-C. Gluckman, and P. N. Fultz. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-546.
54. Girard, M., B. Meignier, F. Barré-Sinoussi, M.-P. Kieny, T. Matthews, E. Muchmore, P. L. Nara, Q. Wei, L. Rimsky, K. Weinhold, and P. N. Fultz. 1995. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69:6239-6248.
55. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
56. Gorse, G. J., S. E. Frey, G. Patel, F. K. Newman, R. B. Belshe, and the NIAID AIDS Vaccine Clinical Trials Network. 1994. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 12:912-918.
57. Graham, B. S., M. J. McElrath, R. I. Connor, D. H. Schwartz, G. J. Gorse, M. C. Keefer, M. J. Mulligan, T. J. Matthews, S. M. Wolinsky, D. C. Montefiori, S. H. Vermund, J. S. Lambert, L. Corey, R. B. Belshe, R. Dolin, P. F. Wright, B. T. Korber, M. C. Wolff, P. E. Fast, AIDS Vaccine Evaluation Group, and Correlates of HIV Immune Protection Group. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. J. Infect. Dis., in press.
58. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331-1339.
59. Graham, B. S., M. C. Keefer, M. J. McElrath, G. J. Gorse, D. H. Schwartz, K. Weinhold, T. J. Matthews, J. R. Esterlitz, F. Sinangil, P. E. Fast, and the NIAID AIDS Vaccine Evaluation Group. 1996. Safety and immunogenicity of a candidate HIV-1 vaccine in health adults: recombinant glycoprotein (rgp120). Ann. Intern. Med. 125:270-279.
60. Haynes, B. F. 1993. Scientific and social issues of human immunodeficiency virus vaccine development. Science 260:1279-1286.
61. Henikoff, S., and J. G. Henikoff. 1993. Performance evaluation of amino acid substitution matrices. Proteins Struct. Funct. Genet. 17:49-61.
62. Henrard, D. R., E. Daar, H. Farzadegan, S. J. Clark, J. Phillips, G. M. Shaw, and M. P. Busch. 1995. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J. Acquired Immune Defic. Syndr. 9:305-310.
63. Hillis, D. M., and J. J. Bull. 1993. An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst. Biol. 42:182-189.
64. Ho, D. D., M. S. C. Fung, Y. Cao, X. L. Li, C. Sun, T. W. Chang, and N.-C. Sun. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
65. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbaksh, K. Kuntsman, D. Erickson, N. R. Landau, J. Phair, D. D. Ho, and R. A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
66. Issel, C. J., D. W. Horohov, D. F. Lea, W. V. Adams, Jr., S. D. Hagius, J. M. McManus, A. C. Allison, and R. C. Montelaro. 1992. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 66:3398-3408.
67. Jurrians, S., B. van Gemen, G. J. Weverling, D. van Strup, P. Nara, R. Coutinho, M. Koot, H. Schuitemaker, and J. Goudsmit. 1994. The natural history of HIV-1 infection: virus load and virus phenotype in determinants of clinical course. Virology 204:223-233.
68. Kahn, J. O., F. Sinangil, J. Baenziger, N. Mumar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. 1994. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1288-1291.
69. Kahn, J. O., K. S. Steimer, J. Baenziger, A.-M. Duliege, M. Feinberg, T. Elbeik, M. Chesney, N. Mumar, D. Chernoff, and F. Sinangil. 1995. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1343-1347.
70. Keet, I. P. M., P. Krijnen, M. Koot, J. M. A. Lange, F. Miedema, J. Goudsmit, and R. A. Coutinho. 1993. Predictors of rapid progression to AIDS in HIV-1 seroconvertors. AIDS 7:51-57.
71. Kent, K. A., and J. Robinson. 1996. Antigenic determinants on HIV-1 envelope glycoproteins: a Dickens of a time with an Oligomer Twist. AIDS 10(Suppl. A):S107-S114.
72. Khadir, A., F. Coutlee, P. Saint-Antoine, C. Olivier, H. Voyer, and A. Kessous-Elbaz. 1995. Clinical evaluation of Amplicor HIV-1 test for detection of human immunodeficiency virus type 1 proviral DNA in peripheral blood mononuclear cells. J. Acquired Immune Defic. Syndr. 9:257-263.
73. Klasse, P. J. 1996. Physico-chemical analyses of the humoral immune response to HIV-1: quantification of antibodies, their binding to viral antigens and neutralization of viral infectivity, p. 22-49. In B. Korber, C. Brander, J. Moore, P. D'Souza, B. Walker, R. Koup, B. Haynes, and G. Myers (ed.), HIV molecular immunology databases, vol. IV. Los Alamos National Laboratory, Los Alamos, N.Mex.
74. Koenig, S., P. Earl, D. Powell, G. Pantaleo, S. Merli, B. Moss, and A. S. Fauci. 1988. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc. Natl. Acad. Sci. USA 85:8638-8642.
75. Korber, B., C. Brander, B. Walker, R. Koup, J. P. Moore, B. Haynes, and G. Myers. 1995. HIV molecular immunology database 1995. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
76. Korber, B., B. H. Hahn, and S. M. Wolinsky. Unpublished data.
77. Korber, B., and G. Myers. 1992. Signature patterns analysis: a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8:1549-1558.
78. Korber, B., S. Wolinsky, B. Haynes, K. Kuntsman, R. Levy, M. Furtado, P. Otto, and G. Myers. 1992. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res. Hum. Retroviruses 8:1461-1465.
79. Korber, B. T. M., R. M. Farber, D. H. Wolpert, and A. S. Lapedes. 1993. Covariation of mutations in the V3 loops of human immunodeficiency virus type 1 envelope protein: an information theoretical analysis. Proc. Natl. Acad. Sci. USA 90:2176-2180.
80. Korber, B. T. M., K. J. Kunstman, B. K. Patterson, M. Furtado, M. M. McEvilly, R. Levy, and S. M. Wolinsky. 1994. Genetic differences between blood-and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481.
81. Korber, B. T. M., G. Learn, J. I. Mullins, B. H. Hahn, and S. M. Wolinsky. 1995. Protecting HIV databases. Nature 378:242-244.
82. Korber, B. T. M., K. MacInnes, R. F. Smith, and G. Myers. 1994. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J. Virol. 68:6730-6744.
83. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
84. Koup, R. A., C. A. Pikora, K. Luzuriaga, D. B. Brettler, E. S. Day, G. P. Mazzara, and J. L. Sullivan. 1991. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J. Exp. Med. 174:1593-1600.
85. Kozak, S. L., E. J. Platt, N. Madani, F. E. Ferro, Jr., K. Peden, and D. Kabat. 1997. CD4, CXCR-4, and CCR-5 dependencies for infection by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71:873-882.
86. Kozlowski, P. A., and S. Jackson. 1992. Serum IgG subclasses and molecular forms in HIV infection: selective increase in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res. Hum. Retroviruses 8:1773-1780.
87. Kutteh, W. H., S. J. Prince, K. R. Hammond, C. C. Kutten, and J. Mestecky. 1996. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin. Exp. Immunol. 104:538-542.
88. Kwok, S., and R. Higuchi. 1989. Avoiding false positives with PCR. Nature 339:237-238.
89. Lafeuillade, A., C. Tamalet, P. de Micco, and C. Thiebaut. 1995. Virological analysis of primary HIV-1 infection with rapid CD4 depletion. AIDS 9:1380-1381.
90. LaRosa, G. J., J. P. Davide, K. Weinhold, J. A. Waterbury, A. T. Profy, J. A. Lewis, A. J. Langlois, G. R. Dreesman, R. N. Boswell, P. Shadduck, C. H. Holley, M. Karplus, D. P. Bolognesi, T. J. Matthews, E. A. Emini, and S. D. Putney. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935.
91. Learn, G. H., Jr., B. T. M. Korber, B. Foley, B. H. Hahn, S. M. Wolinsky, and J. I. Mullins. 1996. Maintaining the integrity of human immunodeficiency virus sequence databases. J. Virol. 70:5720-5730.
92. Lee, T.-H., H. W. Sheppard, M. Reis, D. Dondero, D. Osmond, and M. P. Busch. 1994. Circulating HIV-1 infected cell burden from seroconversion to AIDS: importance of post seroconversion viral load on disease course. J. Acquired Immune Defic. Syndr. 7:381-388.
93. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
94. Lurie, P., M. Bishaw, M. A. Chesney, M. Cooke, M. E. Lemos Fernandes, N. Hearst, E. Katongole-Mbidde, S. Koetsawang, C. P. Lindan, J. Mandel, M. Mkloyi, and T. J. Coates. 1994. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA 271:295-301.
95. Mascola, J. R., J. G. McNeil, and D. S. Burke. 1994. AIDS vaccines. Are we ready for human efficacy trials? JAMA 272:488-489.
96. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, D. S. Burke, and The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
97. Mascola, J. R., M. K. Louder, S. R. Surman, T. C. Vancott, X. F. Yu, J. Bradac, K. R. Porter, K. E. Nelson, M. Girard, J. G. McNeil, F. E. McCutchan, D. L. Birx, and D. S. Burke. 1996. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res. Hum. Retroviruses 12:1319-1328.
98. Matthews, T. J. 1994. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 10:631-632.
99. McElrath, M. J., L. Corey, M. L. Clements, R. Belshe, R. Dolin, B. Graham, P. Fast, T. Matthews, D. Francis, and A. M. Duliege, and the NIAID AIDS Vaccine Trials Network. 1994. A phase II HIV prophylactic vaccine trial in seronegative volunteers: expanded safety and immunogenicity evaluation of two recombinant gp120 vaccines, abstr. 1241, p. 238. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
100. McElrath, M. J., L. Corey, P. D. Greenberg, T. J. Matthews, D. C. Montefiori, L. Rowen, L. Hood, and J. Mullins. 1996. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA 93:3972-3977.
101. McKeating, J. A., A. McKnight, and J. P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effect on infectivity and neutralization. J. Virol. 65:852-860.
102. Mellors, J. W., C. R. Rinald, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
103. Mestecky, J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7:265-276.
104. Mestecky, J., and M. Kilian. 1985. Immunoglobulin A (IgA). Methods Enzymol. 116:37-75.
105. Moore, J. P. 1993. The reactivities of HIV-1 positive human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res. Hum. Retroviruses 9:209-219.
106. Moore, J. P., and R. Anderson. 1994. The WHO and why of HIV vaccine trials. Nature 372:313-314.
107. Moore, J. P., Y. Cao, D. D. Ho, and R. A. Koup. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:5142-5155.
108. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
109. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
110. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A): S117-S136.
111. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
112. Moore, J. P., L. A. Wallace, E. A. C. Follett, and J. A. McKeating. 1989. An ELISA for antibodies to the envelope glycoprotein of divergent strains of HIV-1. AIDS 3:155-163.
113. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
114. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
115. Murthy, K. K., E. K. Cobb, Z. El-Amad, H. Ortega, F. C. Hsueh, W. Satterfield, D. R. Lee, M. L. Kalish, N. L. Haigwood, R. C. Kennedy, K. S. Steimer, A. Schultz, and J. A. Levy. 1996. Titration of a vaccine stock preparation of human immunodeficiency virus type 1 SF-2 in cultured lymphocytes and in chimpanzees. AIDS Res. Hum. Retroviruses 12:1341-1348.
116. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing antibodies against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031-4034.
117. Myers, G., and A. Farmer. 1996. Hidden Markov models and HIV analysis. J. Comp. Biol. 2:24-29.
118. Myers, G., B. T. M. Korber, J. A. Berzofsky, R. F. Smith, and G. N. Pavlakis. 1992. Human retroviruses and AIDS database 1992. Theoretical Biology, Los Alamos National Laboratory, Los Alamos, N.Mex.
119. Myers, G., and R. Lenroot. 1992. HIV glycosylation and what does it portend? AIDS Res. Hum. Retroviruses 8:1459-1460.
120. National Institute of Allergy and Infectious Diseases. 1996. Collection and processing of mucosal specimens. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md.
121. Nyambi, P. N., J. Nkengasong, P. Lewi, K. Andries, W. Janssens, K. Fransen, L. Heyndrickx, P. Piot, and G. van der Groen. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235-6243.
122. O'Brien, T. R., W. A. Blattner, D. Waters, E. Eyster, H. W. Hilgartner, A. R. Cohen, N. Luban, A. Hatzakis, L. M. Aledort, P. S. Rosenberg, W. J. Miley, B. L. Kroner, and J. J. Goedert. 1996. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 276:105-110.
123. O'Brien, W. A., K. Grovit-Ferbas, A. Namazi, S. Ovcak-Derzu, H.-J. Wang, J. Park, C. Yeramian, S.-H. Mao, and J. A. Zack. 1995. Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86:1082-1088.
124. Olsen, G. J., H. Matsuda, R. Hagstrom, and R. Overbeek. 1994. fastDNAml: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood. Comput. Appl. Biosci. 10:41-48.
125. Paxton, W. B., R. W. Coombs, M. J. McElrath, M. C. Keefer, J. Hughes, F. Sinangil, D. Chernoff, L. Demeter, B. Williams, L. Corey, and The National Institute of Allergy and Infectious Diseases AIDS Evaluation Group. 1997. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with >400 CD4 lymphocytes: implications for applying measurements to individual patients. J. Infect. Dis. 175:247-254.
126. Pedersen, C., B. O. Lindhardt, and B. L. Jensen. 1989. Clinical course of primary HIV-1 infection: consequences for subsequent course of infection. Br. Med. J. 299:154-157.
127. Public Health Service. 1994. HIV infection in vaccine trial volunteers. National Institute of Allergy and Infectious Diseases, Bethesda, Md.
128. Rencher, S. D., T. D. Lockey, K. S. Slobod, and J. L. Hurwitz. 1997. Drift from the GPGRAF HIV-1 envelope V3 crown sequence in a North American inner city. AIDS Res. Hum. Retroviruses 13:527-528.
129. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
130. Roos, M. T. L., J. M. A. Lange, R. E. Y. de Goede, R. A. Coutinho, P. T. A. Schellekens, F. Miedema, and M. Tersmette. 1992. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165:427-432.
131. Saag, M. S., M. Holodniy, D. R. Kuritzkes, W. A. O'Brien, R. Coombs, M. E. Poscher, D. M. Jacobsen, G. M. Shaw, D. D. Richman, and P. A. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2:625-629.
132. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type I neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182:185-196.
133. Scandella, C. J., J. Kilpatrick, W. Lidster, C. Parker, J. P. Moore, G. K. Moore, K. A. Mann, P. Brown, S. Coates, B. Chapman, R. R. Masiarz, K. S. Steimer, and N. L. Haigwood. 1993. Non-affinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res. Hum. Retroviruses 9:1233-1244.
134. Schafer, M. E., M. Rhodes, S. Prince, S. M. Michalek, and J. R. McGhee. 1977. A plastic intra-oral device for the collection of human parotid saliva. J. Dent. Res. 56:728-733.
135. Siebelink, K. H. J., E. Tijhaar, R. C. Huisman, W. Huisman, A. de Ronde, I. H. Darby, M. J. Francis, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. 1995.
136. Simmons, G., D. Wilkinson, J. D. Reeves, M. T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P. W. Gray, R. A. Weiss, and P. R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
137. Sinnico, A., R. Fora, M. Sciandra, A. Lucchini, P. Carameelo, and P. Gioannini. 1993. Risk of developing AIDS after primary acute HIV-1 infection. J. Acquired Immune Defic. Syndr. 6:575-581.
138. Smith, R. F., and T. F. Smith. 1990. Automatic generation of primary sequence patterns from sets of related protein sequences. Proc. Natl. Acad. Sci. USA 87:118-122.
139. Smith, R. F., and T. F. Smith. 1992. Pattern-induced multisequence alignment (PIMA) algorithm employing secondary structure-dependent gap penalties for use in comparative protein modeling. Protein Eng. 5:35-41.
140. Strapans, S. I., B. L. Hamilton, S. E. Follansbee, T. Elbeik, P. Barbosa, R. M. Grant, and M. B. Feinberg. 1995. Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182:1727-1737.
141. Sun, N.-C., D. D. Ho, C. R. Y. Sun, R.-S. Liou, W. Gordon, M. S. C. Fung, X.-L. Li, R. C. Ting, T.-H. Lee, N. T. Chang, and T.-W. Chang. 1989. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J. Virol. 63:3579-3585.
142. Takahashi, H., S. Merli, S. D. Putney, R. Houghten, B. Moss, R. N. Germain, and J. A. Berzofsky. 1989. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science 246:118-121.
143. Ten Haaft, P., M. Cornellissen, J. Goudsmit, W. Koornstra, R. Dubbes, N. Niphius, M. Peeters, C. Thiriart, C. Bruck, and J. L. Heeney. 1995. Virus load in chimpanzees infected with human immunodeficiency virus type I: effect of preexposure vaccination. J. Gen. Virol. 76:1015-1020.
144. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
145. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
146. Trkola, A., and J. P. Moore. Unpublished data.
147. Van Cott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitope of HIV-1 envelope glycoproteins by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
148. Van Cott, T. C., V. R. Polonis, L. D. Loomis, N. L. Michael, P. L. Nara, and D. L. Birx. 1995. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV-1. AIDS Res. Hum. Retroviruses 11:1379-1392.
149. Walker, B. D., C. Flexner, T. J. Paradis, T. C. Fuller, M. S. Hirsch, R. T. Schooley, and B. Moss. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66.
150. Walker, B. D., et al. Unpublished data.
151. Wang, S. Z.-S., K. E. Rushlow, C. J. Issel, R. F. Cook, S. J. Cook, M. L. Raabe, Y.-H. Chong, L. Costa, and R. C. Montelaro. 1994. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199:247-251.
152. Weber, J., E.-M. Fenyö, S. Beddows, P. Kaleebu, Å. Björndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
153. Wolinsky, S. M., C. Wike, B. T. M. Korber, C. Hutto, W. P. Parks, L. L. Rosenblum, K. J. Kunstman, M. R. Furtado, and J. L. Munoz. 1992. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255:1134-1137.
154. Wolinsky, S. M., B. T. M. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, J. T. Safrit, and R. A. Koup. 1996. Adaptive evolution of human immunodeficiency virus type 1 during the natural course of infection. Science 272:537-542.
155. World Health Organization. 1995. Scientific and public health rationale for HIV vaccine efficacy trials. AIDS 9:WHO1-WHO4.
156. Wrin, T., and J. H. Nunberg. 1994. HIV-1 MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS 8:1622-1623.
157. Yap, K. L., and G. L. Ada. 1979. The effect of specific antibody on the generation of cytotoxic T lymphocytes and the recovery of mice from influenza virus infection. Scand. J. Immunol. 10:325-332.
158. Zhu, T., H. Mo, N. Wang, D. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261:1179-1181.